Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G McIntyre

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
JTO Clinical and Research Reports|March 23, 2026
First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 TrialsEwa Kalinka, Igor Bondarenko, Miranda Gogishvili, et al.
Emerging Infectious Diseases|June 21, 2021
Pneumococcal Disease Outbreak at a State Prison, Alabama, USA, September 1-October 10, 2018<sup>1</sup>Guillermo V Sanchez, Constance L Bourne, Sherri L Davidson, et al.
Cancer|May 5, 2025
Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50Saadettin Kilickap, Mustafa Özgüroğlu, Ahmet Sezer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2026
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 TrialAna Baramidze, Tamta Makharadze, Miranda Gogishvili, et al.
Cancer Treatment and Research Communications|July 23, 2025
Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapyRolando J Acosta, Debra A G McIntyre, Joseph C Murray, et al.
Epidemiology and Infection|December 7, 2017
Unusually high illness severity and short incubation periods in two foodborne outbreaks of Salmonella Heidelberg infections with potential coincident Staphylococcus aureus intoxicationJ H Nakao, D Talkington, C A Bopp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT StudyJames W Smithy, Hannah L Kalvin, Fiona D Ehrich, et al.
Osteoarthritis and Cartilage Open|January 16, 2026
Identification of alkaline phosphatase as a putative biomarker of anti-NGF treatment-associated arthropathies: Machine learning-assisted analyses of clinical trial dataMatthew F Wipperman, Peter J Ehmann, Debra A G McIntyre, et al.
The Review of Scientific Instruments|January 1, 2018
Effects of transients in LIGO suspensions on searches for gravitational wavesM Walker, T D Abbott, S M Aston, et al.
Physical Review Letters|April 29, 2017
First Demonstration of Electrostatic Damping of Parametric Instability at Advanced LIGOCarl Blair, Slawek Gras, Richard Abbott, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
JTO Clinical and Research Reports|March 23, 2026
First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 TrialsEwa Kalinka, Igor Bondarenko, Miranda Gogishvili, et al.
Emerging Infectious Diseases|June 21, 2021
Pneumococcal Disease Outbreak at a State Prison, Alabama, USA, September 1-October 10, 2018<sup>1</sup>Guillermo V Sanchez, Constance L Bourne, Sherri L Davidson, et al.
Cancer|May 5, 2025
Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50Saadettin Kilickap, Mustafa Özgüroğlu, Ahmet Sezer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2026
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 TrialAna Baramidze, Tamta Makharadze, Miranda Gogishvili, et al.
Cancer Treatment and Research Communications|July 23, 2025
Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapyRolando J Acosta, Debra A G McIntyre, Joseph C Murray, et al.
Epidemiology and Infection|December 7, 2017
Unusually high illness severity and short incubation periods in two foodborne outbreaks of Salmonella Heidelberg infections with potential coincident Staphylococcus aureus intoxicationJ H Nakao, D Talkington, C A Bopp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT StudyJames W Smithy, Hannah L Kalvin, Fiona D Ehrich, et al.
Osteoarthritis and Cartilage Open|January 16, 2026
Identification of alkaline phosphatase as a putative biomarker of anti-NGF treatment-associated arthropathies: Machine learning-assisted analyses of clinical trial dataMatthew F Wipperman, Peter J Ehmann, Debra A G McIntyre, et al.
The Review of Scientific Instruments|January 1, 2018
Effects of transients in LIGO suspensions on searches for gravitational wavesM Walker, T D Abbott, S M Aston, et al.
Physical Review Letters|April 29, 2017
First Demonstration of Electrostatic Damping of Parametric Instability at Advanced LIGOCarl Blair, Slawek Gras, Richard Abbott, et al.
Pageof 13